MORPHIC HOLDING, INC. : Other Events (form 8-K)

Item 8.01 Other Events

On January 5, 2021, Morphic Holding, Inc. ("Morphic") announced the expansion of its research and development collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration expansion involves the initiation of work on a third integrin target, with the collaboration scope to include activating antibodies against this new target. The agreement was facilitated by Johnson & Johnson Innovation.

Under the terms of the original collaboration agreement, Morphic will receive a milestone payment for initiating work on the third target. As part of the expansion, any new product candidates will be subject to milestones and royalties.

© Edgar Online, source Glimpses